Tag: Dopaminergic neurons

Glutathione depletion and overproduction both initiate degeneration of nigral dopaminergic neurons

This 2011 study investigated how both glutathione (GSH) deficiency and excess affect the viability of nigral dopaminergic neurons, key cells involved in Parkinson’s disease (PD). Using a viral vector-based RNA interference model in rats, researchers modulated the synthesis of GSH by targeting glutamate–cysteine ligase subunits. Both decreased and increased GSH

Read More »

α-lipoic acid exerts neuroprotective effects on neuronal cells by upregulating the expression of PCNA via the P53 pathway in neurodegenerative condition

This 2016 in vitro study investigated the neuroprotective effects of α-lipoic acid (ALA) on dopaminergic neurons exposed to MPP+, a neurotoxin used to model Parkinson’s disease. The researchers found that ALA treatment significantly reduced neuronal apoptosis and increased the expression of proliferating cell nuclear antigen (PCNA), a key protein involved

Read More »

The Endotoxin Hypothesis of Parkinson’s Disease

This review explores the “endotoxin hypothesis” of Parkinson’s disease (PD), suggesting that elevated levels of lipopolysaccharide (LPS) from gut dysfunction contribute to PD progression. LPS promotes α-synuclein aggregation, microglial activation, neuroinflammation, and dopaminergic neuron loss in the brain. The hypothesis posits that gut-derived LPS and cytokines induce systemic inflammation, which

Read More »

Methylene blue protects dopaminergic neurons against MPTP-induced neurotoxicity by upregulating brain-derived neurotrophic factor

This study investigates the neuroprotective effects of methylene blue (MB) in Parkinson’s disease (PD) models, revealing that MB prevents dopaminergic neuron loss and mitigates dopamine depletion by upregulating brain-derived neurotrophic factor (BDNF) and activating Erk signaling pathways. The results highlight that MB’s protective role is associated with BDNF activation, which

Read More »